Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily

Banham, Alison H.; Colonna, Marco; Cella, Marina; Micklem, K. J.; Pulford, Karen; Willis, Antony C.; Mason, David Y.

doi:10.1002/jlb.65.6.841

Cited by 55 publications

(32 citation statements)

References 15 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, evidence is provided that, in addition to CD152, the inhibitory molecule CD85/LIR-1/ILT2 is expressed by all T lymphocytes and that it is capable of down-regulating T cell function. It was previously reported that CD85/LIR-1/ILT2 is expressed on a proportion of T cells, as it has been detected on the surface of 4 -20% of CD3 ϩ lymphocytes (6,8,(13)(14)(15). Using the HP-F1 mAb to assess expression of CD85/LIR-1/ILT2, only a fraction of resting T lymphocytes was found positive.…”

Section: Discussionmentioning

confidence: 96%

“…mAbs specific for LIR-1/ILT2 have been produced, namely HP-F1, M402, and M405 (8,12). In addition, mAb VMP55 and GHI/75, defined at the Fifth Workshop on Leukocyte Ags as specific for CD85 (13,14), have been recently shown to recognize the LIR-1/ILT2 inhibitory receptor (15), because anti-CD85 mAb react with ILT2 transfectants. In addition, peptide maps of the CD85 Ag are identical with those of ILT2.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The CD85/LIR-1/ILT2 Inhibitory Receptor Is Expressed by All Human T Lymphocytes and Down-Regulates Their Functions

Saverino

Fabbi²,

Ghiotto

et al. 2000

The Journal of Immunology

133

128

View full text Add to dashboard Cite

The inhibitory molecule CD85/LIR-1/ILT2 has been detected previously on the surface of a small proportion of T lymphocytes. In this study, evidence is provided that, although only a fraction of CD3+ cells are stained by mAb specific for CD85/LIR-1/ILT2 on their surface, this inhibitory receptor is present in the cytoplasm of all T lymphocytes, and that it is detectable on the surface of all T cell clones by the M402 mAb. Biochemical analyses further demonstrate that CD85/LIR-1/ILT2 is present in all T clones analyzed, and that the protein is tyrosine-phosphorylated. Expression of mRNA coding for CD85/LIR-1/ILT2 has been assessed by RT-PCR. Notably, in the NKL cell line and in one T cell clone, amplification of the messenger required 30 cycles only, whereas, in other T cell clones, an amplification product was detected by increasing the number of cycles. CD85/LIR-1/ILT2 inhibits CD3/TCR-mediated activation in both CD4+ and CD8+ clones, and it down-regulates Ag recognition by CD8+ cells in a clonally distributed fashion. Addition of anti-ILT2 HP-F1 mAb in the cytolytic assay enhances target cell lysis mediated by Ag-specific CTL. This could be due to interference of the mAb with receptor/ligand interactions. In contrast, HP-F1 mAb cross-linking triggers inhibitory signals that reduce cytotoxicity. CD85/LIR-1/ILT2 also controls responses to recall Ags and, in low responders, its engagement sharply increases T cell proliferation. The inhibitory function of the molecule is also confirmed by its ability to reduce CD3/TCR-induced intracellular Ca2+ mobilization.

show abstract

Section: Discussionmentioning

confidence: 96%

mentioning

confidence: 99%

The CD85/LIR-1/ILT2 Inhibitory Receptor Is Expressed by All Human T Lymphocytes and Down-Regulates Their Functions

Saverino

Fabbi²,

Ghiotto

et al. 2000

The Journal of Immunology

133

128

View full text Add to dashboard Cite

show abstract

“…It associates with b 2 -microglobulin (b2m) [16] and binds peptides [17], but unlike HLA-I it has 13 potential N-linked glycosylation sites [7]. To date, the only molecule shown to be able to bind to UL18 is the inhibitory receptor LIR-1/ILT2/CD85j [11,18], which will be referred to as leukocyte Ig-like receptor (LIR)-1 in the rest of this report. LIR-1 is a member of a family of proteins (LIR-1 to LIR-8), related to other NK cell inhibitory receptors (e.g.…”

Section: Molecular Immunologymentioning

confidence: 99%

Spontaneous mutations in the human CMV HLA class I homologue UL18 affect its binding to the inhibitory receptor LIR‐1/ILT2/CD85j

et al. 2006

View full text Add to dashboard Cite

Human cytomegalovirus (HCMV) down-regulates cell surface expression of HLA class I molecules (HLA-I). UL18, an HCMV-encoded HLA-I homologue, has been proposed to protect virus-infected cells against NK cell recognition by engaging the inhibitory receptor leukocyte Ig-like receptor (LIR)-1, which also binds a broad spectrum of HLA-I alleles, including HLA-G1. Because genetic and biological differences exist among HCMV strains, we characterized laboratory (AD169) and clinical (4636, 13B, 109B) strain-derived UL18 proteins. Compared to the known AD169-derived UL18, mutations were found in clinical strain-derived UL18. They were clustered in the a3 domain (13B), previously shown to be critical for LIR-1 binding, or in the a1 domain (4636). In cytotoxicity assays, pretreatment of LIR-1 + NKL with soluble 4636-UL18 completely abolished LIR-1-dependent protection from NK lysis, conferred by the expression of HLA-G1 on target cells (721.221-HLA-G1 + ). Similarly, flow cytometry, Biacore and ELISA experiments showed 4636-UL18 and 13B-UL18 to have the strongest binding capacity to LIR-1. Our results suggest the importance of two independent UL18 regions for LIR-1 binding, one localized on the tip of the a3 domain, and another composed of two loops that emerge from the a1 domain. Strain variations in these domains may result in different UL18-mediated effects on LIR-1 + cells during the course of HCMV infection.

show abstract

“…CD85 was originally defined at the Fifth Workshop on Leukocyte Antigens by two monoclonal antibodies, VMP55 and GHI/75 [39], and has been recently shown to correspond to ILT2, since tryptic peptide sequences of CD85 match ILT2 amino acid sequence, and both of the original anti-CD85 mAbs stain ILT2 transfectants [40]. Particularly high levels of CD85-ILT2 are expressed by neoplastic plasma cells and by hairy cell leukemia B cells.…”

Section: Ilt Receptors Are Expressed On Lymphoid And/or On Myeloid Cellsmentioning

confidence: 99%

A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells

Colonna

Nakajima

Navarro

et al. 1999

Journal of Leukocyte Biology

Self Cite

154

109

View full text Add to dashboard Cite

Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily

Cited by 55 publications

References 15 publications

The CD85/LIR-1/ILT2 Inhibitory Receptor Is Expressed by All Human T Lymphocytes and Down-Regulates Their Functions

The CD85/LIR-1/ILT2 Inhibitory Receptor Is Expressed by All Human T Lymphocytes and Down-Regulates Their Functions

Spontaneous mutations in the human CMV HLA class I homologue UL18 affect its binding to the inhibitory receptor LIR‐1/ILT2/CD85j

A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells

Contact Info

Product

Resources

About